Table 1.
Baseline patient characteristics.
| Characteristic | Total (n = 259) |
|---|---|
| Age (years), median (IQR) | 65 (56–70) |
| Sex, n (%) | |
| Male | 172 (66.4) |
| Female | 87 (33.6) |
| ECOG PS, n (%) | |
| 0 | 72 (27.8) |
| 1 | 159 (61.4) |
| 2 | 28 (10.8) |
| ICIs, n (%) | |
| Nivolumab | 160 (61.8) |
| Pembrolizumab | 99 (38.2) |
| Treatment line, n (%) | |
| First-line | 64 (24.7) |
| Second-line | 128 (49.4) |
| ≥Third-line | 67 (25.9) |
| Baseline concomitant medication, n (%) | |
| Corticosteroids | 45 (17.4) |
| PPIs | 108 (41.7) |
| Antibiotics | 36 (13.9) |
| Metformin | 6 (2.3) |
| Fibrates | 2 (0.8) |
| Statins | 18 (6.9) |
| NSAIDs | 97 (37.5) |
| Peripheral blood counts at baseline (cells/mm3), median (IQR) | |
| Absolute neutrophil count | 4824 (3531–6186) |
| Absolute lymphocyte count | 1316 (914–1697) |
| NLR, median (IQR) | 3.7 (2.5–6.2) |
IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; PPI, proton pump inhibitor; NSAID, nonsteroidal anti-inflammatory drug; NLR, neutrophil-to-lymphocyte ratio.